Immunotherapy plus radiation shows promise against rare sarcomas

NCT ID NCT03474094

Ongoing Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard radiotherapy improves outcomes for people with soft tissue sarcoma. About 62 participants will receive treatment in different sequences: radiation before or after surgery, combined with atezolizumab. The main goal is to see if the combination leads to more tumor cell death (necrosis) compared to radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab (an immunotherapy drug) and radiotherapy
What this could lead to: If successful, this could point toward a new treatment approach that combines immunotherapy with radiotherapy to better control soft tissue sarcoma before or after surgery.
What could go wrong: This is an early Phase 2 trial with only 62 participants, so results may not apply to all patients. The combination may cause side effects like immune-related inflammation or radiation toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA, SOFT TISSUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA, SOFT TISSUE

Contacts and locations

Show contact details

Locations

Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, France
Institut Bergonie

Bordeaux, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Gustave Roussy

Villejuif, 94805, France
Royal Marsden Hospital

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.